Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Research paper

Mechanical ventilation and mortality among 223 critically ill patients with coronavirus disease 2019: A multicentric study in Germany

Kevin Roedl, MD a,*, 1
Dominik Jarczak, MD a, 1
Liina Thasler, MD a
Martin Bachmann, MD b
Frank Schulte, MD c
Berthold Bein, MD d
Christian Friedrich Weber, MD e
Ulrich Schäfer, MD f
Carsten Veit, MD g
Hans-Peter Hauber, MD h
Sebastian Kopp, MD i
Karsten Sydow, MD j
Andreas de Weerth, MD k
Marc Bota, MD l
Rüdiger Schreiber, MD m
Oliver Detsch, MD n
Jan-Peer Rogmann, MD o
Daniel Frings, MD a
Barbara Sensen, MD a
Christoph Burdelski, MD a
Olaf Boenisch, MD a
Axel Nierhaus, MD a
Geraldine de Heer, MD a, 1
Stefan Kluge, MD a, 1

a Department of Intensive Care Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
b Department of Pneumonology and Intensive Care Medicine, Weaningcenter, Asklepios Hospital Barmbek, Hamburg, Germany
c Department of Anaesthesiology, Intensive Care and Respiratory Medicine, Asklepios Hospital Harburg, Hamburg, Germany
d Department of Anaesthesiology, Intensive Care, Emergency Medicine and Pain Medicine, Asklepios Hospital St. Georg, Hamburg, Germany
e Department of Anaesthesiology, Intensive Care and Emergency Medicine, Asklepios Hospital Wandsbek, Hamburg, Germany
f Department of Cardiology, Angiology and Intensive Care Medicine, Marien Hospital, Hamburg, Germany
g Department of Interdisciplinary Intensive Care Medicine, Bundeswehr Hospital, Hamburg, Germany
h Department of Anaesthesiology and Intensive Care Medicine, Asklepios Hospital Altona, Hamburg, Germany
i Department of Anaesthesiology and Intensive Care Medicine, Amalie Sieveking Hospital, Hamburg, Germany
j Department of Anaesthesiology and Intensive Care Medicine, Asklepios West Hospital Hamburg, Hamburg, Germany
k Department of Internal Medicine, Bethesda Hospital Bergedorf, Hamburg, Germany
l Department of Anaesthesiology and Intensive Care Medicine, Asklepios Hospital Nord, Hamburg, Germany
m Department of Anaesthesiology and Intensive Care Medicine, Israelitic Hospital, Hamburg, Germany

* Corresponding author. Department of Intensive Care Medicine, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany. Tel.: +49 40 7410 57020; fax: +49 40 7410 57011.
E-mail address: k.roedl@uke.de (K. Roedl).

1 Authors contributed equally.

https://doi.org/10.1016/j.aucc.2020.10.009
1036-7314/© 2020 Australian College of Critical Care Nurses Ltd. Published by Elsevier Ltd. All rights reserved.
1. Background

Originating from China, a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in December 2019. SARS-CoV-2 was detected as a cause of coronavirus disease 2019 (COVID-19) in lower respiratory tract samples. The virus spread is causing an ongoing global pandemic. COVID-19 led to high hospitalisation rates worldwide and confronted the healthcare systems with an enormous challenge. The clinical spectrum of COVID-19 ranges from asymptomatic to severe illness, with development of acute respiratory distress syndrome (ARDS) and multiple organ failure. About 17% of hospitalised patients with COVID-19 need admission to the intensive care unit (ICU). Certain clinical characteristics and risk factors have been previously reported to be associated with worse outcomes, especially in patients with pre-existing medical conditions and older patients.

Patients with COVID-19 treated at the ICU suffer from high mortality; in patients with invasive mechanical ventilation (MV), rates from 50% to 97% have been reported. However, some studies were preliminary and included patients without a completed ICU stay. Furthermore, numerous studies were conducted in regions with overwhelmed healthcare systems, which possibly led to a resource limitation as a result of higher mortality rates. Furthermore, owing to high risk of infection via respiratory aerosols, potential aerosol-generating procedures such as noninvasive ventilation (NIV) or high-flow nasal cannula (HFNC) therapy are a matter of concern. Avoidance of NIV/HFNC therapy and early tracheal intubation has been suggested as a management strategy for COVID-19; however, this is controversial owing to the worse outcomes reported with tracheal intubation. Data on outcomes after critical illness in patients with COVID-19 and outcomes of patients requiring MV are limited. Therefore, the aim of this study was to investigate clinical characteristics and outcomes of MV in critically ill patients with COVID-19 in a large cohort in Germany.

2. Methods

2.1. Study design, setting, and ethics

We conducted a retrospective multicentre observational study and included all critically ill adult patients with COVID-19 who completed an ICU stay and who were treated in the ICUs of the University Medical Center Hamburg-Eppendorf and 14 teaching hospitals in Hamburg (the second largest city in Germany, with 1.8 million inhabitants) between February 1, 2020, and June 3, 2020. The participating hospitals were Agaplesion Diakonie Hospital, Albertinen Hospital, Amalie-Sieveking Hospital, Asklepios Hospital Altona, Asklepios Hospital Barmbek, Asklepios Hospital Harburg, Asklepios Hospital North, Asklepios Hospital St. Georg, Asklepios Hospital Wandsbek, Asklepios West Hospital Hamburg, Bethesda Hospital Bergedorf, Bundeswehr Hospital Hamburg, Israelitic Hospital, and Marien Hospital. Furthermore, epidemiological data about the number of hospitalised patients were enquired at the Hamburg health authorities for the aforementioned time frame. The study was approved by the local clinical institutional review board and complies with the Declaration of Helsinki. The Ethics Committee of the Hamburg Chamber of Physicians was informed about the study.

2.2. Inclusion and exclusion criteria

We included all consecutive adult patients (≥18 years) with confirmed COVID-19 and COVID-19–associated critical illness.
admitted to one of the ICUs in the participating hospitals. Confirmed COVID-19 was defined as at least one positive result on reverse transcriptase polymerase chain reaction obtained from nasopharyngeal swabs and/or bronchial secretions. Patients with noncompleted ICU stay (ongoing ICU treatment) were excluded.

3.2. Baseline characteristics of the study population

Detailed demographic and baseline characteristics are shown in Table 1. Comorbidities, represented by the CCI, were a median of 1 (0–2) point. arterial hypertension was the leading comorbidity (49%, n = 108). Forty-five (20%) patients had ongoing treatment with angiotensin-converting-enzyme (ACE) inhibitors, and 42 (19%) patients had treatment with angiotensin receptor blockers. Further common comorbidities were diabetes mellitus (type II), history of active haematologic or oncologic disease, and chronic respiratory disease in 27% (n = 59), 20% (n = 44), and 18% (n = 40) of patients, respectively. The majority of patients were admitted to the ICU owing to respiratory deterioration. Most common symptoms on ICU admission were shortness of breath and fever in 124 patients (56%) each. Further symptoms were productive cough in 55 (25%), fatigue in 49 (22%), nonproductive cough in 34 (15%), and myalgia in 11 (5%) patients. Seventy-five patients (34%) needed vasopressor support on the day of admission to the ICU.

3.3. Ventilatory support, ARDS management, and COVID-19 therapy

Of 223 patients, 167 (75%) received MV during the ICU stay. The median time from admission to initiation of invasive MV was 1 (0–2) day. Eighty-nine (40%) patients required invasive MV within the first day of ICU admission. Furthermore, NIV and HFNC therapy were used in 18 (8%) and 22 (10%) patients, respectively, within the first day, and in 31 (14%) and 26 (12%) patients during their ICU stay. Subsequent invasive MV due to NIV/HFNC therapy failure was necessary in 23 of 31 (74%) patients who underwent NIV and 23 of 26 (88%) patients who underwent HFNC therapy. One hundred sixty-three (73%) developed ARDS. As per the PaO2/FiO2 ratio, ARDS was diagnosed as mild (4%, n = 12), moderate (42%, n = 70), and severe (49%, n = 81). Owing to severe ARDS, 20 patients received extracorporeal membrane oxygenation (ECMO). Initial mechanical ventilator settings were a positive end-expiratory pressure (PEEP) of 12 (10–15) cmH2O, respiratory rate of 22 (20–28), FiO2 of 0.6 (0.5–0.8), and inspiratory pressure of 25 (19–29) cmH2O (median values). For further ARDS treatment, 105 (65%) mechanically ventilated patients were placed in prone position, 37 (22%) received neuromuscular blockade, and 19 (11%) patients inhaled nitric oxide. In patients receiving prone positioning with the first days of the ICU stay, 62% responded; the median PaO2 before and after prone positioning was 73.3 (64.2–78.7) and 78.7 (68.3–79.7) mmHg in responders and 72.8 (62.5–77.5) and 62.4 (59.3–73) mmHg in nonresponders, respectively. The median duration of MV was 15 (8–25) days. Self-proning was performed in four patients in the non-MV group. In 73 (33%) patients, RRT was initiated. Systemic glucocorticoid treatment was initiated in 51 (23%) of patients. Experimental antiviral treatment with hydroxychloroquine was used in 11 (5%) patients and lopinavir–ritonavir treatment was initiated in 10 (4%) patients.

3.4. Differences between patients with and without MV

Clinical findings concerning baseline characteristics, interventions, and complications are summarised in Table 2. No differences were observed in age and gender; body mass index was significantly higher (p < 0.05) in mechanically ventilated patients. Severity of illness represented by a median SOFA score on admission and after 24 h was 5 (3–9) and 9 (4–12), respectively. The SOFA score on admission and after 24 h was significantly higher in the MV group (both p < 0.001). Vasopressor use within the first 24 h after admission was significantly higher in patients with MV (71% vs. 5%, p < 0.001). RRT was initiated in 73 (33%) patients in the whole cohort and was used more frequently in mechanically
ventilated patients (p < 0.001). Therapeutic anticoagulation was used in 121 (54%) patients overall and was distributed equally in both groups. Use of antibiotic, antifungal, and antiviral therapy was common in both groups; use of antibiotic therapy was significantly more frequent in mechanically ventilated patients (p < 0.001). Pre-existing obesity (body mass index > 30 kg/m²) and diabetes mellitus type II were significantly higher in patients with MV (p = 0.045 and 0.036, respectively). Patients with chronic respiratory disease were more frequent among patients in the non-MV group. Laboratory and blood gas analyses are summarised in Supplementary Table 1. Significant differences were found in admission in terms of PaO₂, PaCO₂, and pH after 24 h. As to clinical chemistry, we observed significantly higher values in creatinine and liver function parameter (including bilirubin, Aspartat-Aminotransferase (ASAT), Alanin-Aminotransferase (ALAT)) in the MV group. Markers of inflammation were significantly lower in the patients in the non-MV group. Logistic regression analysis revealed that the SOFA score on admission (odds ratio [OR] = 1.360; 95% confidence interval [CI] = 1.184–1.562; p < 0.001), septic shock (OR = 3.946; 95% CI = 1.005–9.231; p = 0.049), and RRT (OR = 4.909; 95% CI = 1.319–18.275; p = 0.018) were significantly associated with the need for MV after adjusting for confounders (see Supp. Table 2a).

3.5. Overall outcome and complications

In our cohort of 223 critically ill patients with COVID-19, 78 patients died, resulting in an overall ICU mortality rate of 35%. We observed a mortality rate of 44% (n = 74) in mechanically ventilated patients and 7% (n = 4) in patients in the non-MV group. All four patients dying in the non-MV group had severe hypoxaemia and/or
multiple organ failure; therapy was limited based on the existing advance directive. The mortality of patients receiving ECMO was 65% (n = 13). Overall, the median length of ICU stay was 13 (5–24) days. The following complications were observed during the ICU stay: 90 (40%) patients suffered from septic shock, and 17 (8%) patients had heart failure. Deep vein thrombosis or pulmonary embolism was detected in 18 (8%) and 14 (6%) of patients.

3.6. Factors associated with mortality in mechanically ventilated patients

Findings concerning survival and nonsurvival of mechanically ventilated patients are shown in Table 3 and Fig. 1. Of 167 patients, 93 (56%) survived the ICU stay. Survivors after MV were significantly younger (65 vs. 72 years; p = 0.001). Severity of illness, represented by the SOFA score and CCI, was significantly higher in nonsurvivors. Regarding ventilatory settings, we did not find significant differences. Use of ECMO and adjunctive therapies (glucocorticoid treatment, inhaled vasodilatory treatment) were more common in nonsurvivors. Need for RRT was frequent in nonsurvivors compared with survivors (62% vs. 26%, respectively; p < 0.001). Complications during the ICU stay were more common in nonsurvivors compared with survivors (62% vs. 26%, respectively; p = 0.001). Need for RRT was frequent in nonsurvivors compared with survivors (62% vs. 26%, respectively; p = 0.001).

Table 2

Differences between therapies and complications in ICU patients with COVID-19 in the mechanical ventilation (MV) group and non-MV group during the ICU stay.

| Parameters | All (n = 223) | MV (n = 167) | No MV (n = 56) | p-value |
|------------|--------------|-------------|---------------|---------|
| Procedures/therapies | | | | |
| Vasopressors (first 24 h) | 123 (55) | 119 (71) | 4 (5) | <0.001 |
| Renal replacement therapy | 73 (33) | 70 (42) | 3 (5) | <0.001 |
| Therapeutic anticoagulation | 121 (54) | 102 (61) | 19 (34) | 0.185 |
| Antibiotic therapy | 197 (8) | 161 (96) | 36 (64) | <0.001 |
| Antifungal therapy | 25 (11) | 20 (12) | 5 (9) | 0.363 |
| Antiviral therapy | 42 (19) | 32 (19) | 10 (18) | 0.504 |
| Experimental therapy | | | | |
| - Hydroxychloroquine | 11 (5) | 11 (7) | 0 (0) | 0.038 |
| - Specific antiviral therapy | 10 (4) | 8 (5) | 2 (4) | 0.520 |
| - Glucocorticoid treatment | 51 (23) | 46 (28) | 5 (9) | 0.012 |
| Complications during ICU stay | | | | |
| Heart failure | 17 (8) | 15 (9) | 2 (4) | 0.151 |
| Pulmonary embolism | 14 (6) | 13 (8) | 1 (2) | 0.092 |
| Deep vein thrombosis | 18 (8) | 12 (7) | 6 (11) | 0.280 |
| Cardiac arrest | 25 (11) | 23 (14) | 2 (4) | 0.048 |
| Myocardial infarction | 7 (3) | 3 (2) | 4 (7) | 0.068 |
| DIC | 5 (2) | 5 (3) | 0 (0) | 0.232 |
| Septic shock | 90 (40) | 85 (51) | 5 (9) | <0.001 |
| Ventilation/ventilatory support | | | | |
| Mechanical ventilation | 167 (75) | 167 (100) | – | – |
| ECMO | 20 (9) | 20 (12) | – | – |
| Other ventilation support | | | | |
| - High-flow nasal cannula | 31 (14) | 23 (14) | 8 (14) | 0.540 |
| - Noninvasive ventilation | 26 (12) | 23 (14) | 3 (6) | 0.066 |
| Duration of ventilation (days) | 15 (8–25) | 15 (8–25) | – | – |

Data are expressed as n (%) or median (interquartile range); p-value: MV vs. non-MV. Bold intends a significant p-value in the far right column.

BMI, body mass index; kg, kilogram; m, metre; DIC, disseminated intravascular coagulation; SOFA, Sequential Organ Failure Assessment; ECMO, extracorporeal membrane oxygenation; ICU, intensive care unit.

We hereby report on a large observational cohort study on critically ill patients with COVID-19 from Germany. To our knowledge, this is the first reported study on a cohort of critically ill patients with COVID-19 in whom clinical characteristics and outcomes after MV were investigated, including only patients with a completed ICU stay. We demonstrated an overall ICU mortality rate of 35% and a mortality rate of 44% among patients who received MV.

In our representative cohort, 75% of patients required invasive MV. Overall, NIV and HFNC therapy was used in 12% and 14% of patients, respectively. Eighty-one percent (46 of 57) of patients needed MV after NIV or HFNC therapy. However, a previous small study reported a rate of 41% HFNC therapy failure in patients with COVID-19.25 Recently, a meta-analysis compared different forms of respiratory support in patients without COVID-19 and with respiratory failure, which encompassed 25 trials. In this analysis, NIV was associated with lower mortality than standard oxygen therapy. Furthermore, NIV and HFNC therapy were associated with lower rates of endotracheal intubation.26 Nevertheless, it is unclear whether the application of HFNC therapy/NIV or early intubation and subsequent MV is preventing COVID-19 progression.27 In our cohort, we observed that 40% of patients required MV within the first day of ICU admission. Furthermore, NIV was used in 11% and HFNC therapy in 13% of patients within the first day after admission. In spontaneously breathing patients with an indication for HFNC therapy or NIV immediately after admission, the time to intubation was a median of only 1 day. Overall, 75% of admitted patients received MV, which is higher than that in other studies recently reported.27,28 However, our findings are comparable with two large trials in Germany on MV recently reported.29,30 But differences may be explained by different ICU admission strategies and some of the hospitals serving as ARDS referring centres specialised in treatment of ARDS and providing ECMO support. The median duration of invasive MV was 15 days comparable with previous reports on patients with ARDS of non–COVID-19 origin.31 Richardson et al.3 demonstrated a rather low mortality of 25%, in patients with COVID-19 who received MV, but more than 70% of...
reported patients were undergoing ICU treatment at the end of the study period, resulting in a biased outcome with regard to mortality. One recent study reporting of 165 critically ill mechanically ventilated patients with COVID-19 observed a mortality rate of 36%, with only a small number of patients still ventilated. In our cohort, we observed a mortality rate of 44% among mechanically ventilated patients. The differences in mortality between studies can be explained by several observations. First, several studies
report on cohorts with incomplete outcomes for large proportions of patients, when the studies were submitted. This prevents an actual statement on mortality. Second, to date, many studies have been reported from regions that have seen a rapid rise in SARS-CoV-2–positive patients, leading to significant resource limitation. Owing to the overwhelming number of patients admitted to hospitals in China (Wuhan), Italy (Lombardi Region), and the US (New York), local healthcare systems were over their maximal capacities, possibly leading to intubation avoidance and rationing of medical therapies.3,6,7 Hereby, we report on a region with overall 5096 cases during the study period and 996 being hospitalised. The total number of ICU beds was increased by 57% in the city of Hamburg. Luckily, the region of northern Germany was not overwhelmed with COVID-19 cases, so we were able to prepare sufficiently and systematically for the pandemic. Patients were likely admitted early to ICU facilities and received early ventilatory support in a sufficiently staffed intensive care setting without shortage of ventilators. However, in a setting without resource limitations, we could show that the observed mortality rate is comparable with patients without COVID-19 and with ARDS.31 Several studies have reported on use of ECMO in patients with COVID-19. However, the outcome of patients treated with ECMO owing to ARDS caused by COVID-19 is unclear. A recent report from China with 21 of 129 (16%) critically ill patients receiving ECMO reported a mortality of 57%.33 In our study, 9% of our patients received ECMO. The mortality among patients receiving ECMO in our cohort was 65% and considerably higher than previous studies on ARDS.34 This may be explained by different management strategies and reporting of patients with virus-induced ARDS only.

In our cohort, we observed different parameters potentially associated with mortality. Both older age and comorbidities were associated with mortality as previously reported.44 Furthermore, as expected, patients with more severe ARDS had worse outcomes. Furthermore, we observed no differences in outcomes with regard to time of initiation of invasive MV. However, mortality was associated with use of adjunctive therapies—glucocorticoid treatment, inhaled vasodilatory treatment—but not prone positioning or neuromuscular blockade for ARDS treatment. The neuromuscular blockade rate in our cohort was rather low, and national guidelines suggest the use of neuromuscular blockade in selected cases only. Our study found that higher lactate, lower pH, and lower PaO2 values after 24 h were associated with worse outcomes. Procedures and complications during the ICU stay were frequent: necessity of RRT, septic shock, and cardiac arrest were significantly associated with mortality. These findings are in line with previous studies.5,35 Twelve percent of patients suffered from clinically detected pulmonary embolism, and this was also related to mortality in mechanically ventilated patients. Thromboembolic events are frequently observed in autopsy studies, representing yet another potentially life-threatening complication in critically ill patients with COVID-19.40 These findings led to recommendation of, at least, prophylactic anticoagulation in critically ill patients with COVID-19.37 This study has several strengths. First, we exclusively report on patients with a completed ICU stay, which allows firm conclusions regarding outcomes to be drawn. Second, we report on a representative sample of critically ill patients with COVID-19 treated during the study period. Some limitations should be mentioned. First, data derived from an observational cohort from different hospitals. Different management and therapy strategies of patients with COVID-19 requiring MV and influence on outcomes cannot be entirely excluded. Second, some cases had incomplete documentation based on missing laboratory testing. Third, we observed a rather high rate of complications (e.g., septic shock, cardiac arrest), and a more detailed analysis could not be performed as per retrospective data collection using the CRF. Fourth, residual confounding of unmeasured covariates is a matter of concern and cannot be entirely excluded.

5. Conclusions

In a large multicentre observational cohort study of 223 critically ill patients with COVID-19, we observed an ICU mortality of 35%, an MV rate of 75%, and a mortality rate of 44% in patients receiving MV. Septic shock was a common complication in this cohort. Future randomised trials should focus on the impact of NIV strategies and on the application of adjunctive therapies in patients with COVID-19.

Availability of data and materials

The data sets supporting the conclusions of this article are included within the article.
Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Conflict of Interest

K.R., D.J., LT, M.B., F.S., C.F.W., U.S., C.V., H.-P.H., S.Ko., K.S., A.d.W., M.B., R.S., O.D., J.-P.R., B.S., C.B., O.B., B.B., and G.d.H. do not report any conflicts of interest. S.K. received research support from Ambu, E.T.View Ltd., Fisher & Paykel, Pfizer, and Xenios; lecture honoraria from ArjoHuntleigh, Astellas, Astra, Basilea, Bard, Baxter, Biotest, CSL Behring, CytoSorbents, Fresenius, Gilead, MSD, Orion, Pfizer, Philips, Sedana, Sorin, Xenios, and Zoll; and consultant honorarium from AMOMED, Astellas, Bayer, Basilea, Bard, Baxter, Biotest, Philips, Sedana, Sorin, and Xenios. A.N. received research funds, lecture honoraria, and travel reimbursement within the last 5 years from CytoSorbents Europe, Biotest AG, and Thermo Fisher Scientific. D.F. reports lecture honoraria within the last 5 years from Xenios AG.

CRediT authorship contribution statement

KR, DJ, GdH, LT and SK participated in study conception and design. KR, DJ, LT, MB, FS, CFW, US, CV, HPH, Sko, KS, AdW, MB, RS, OD, JPR, BS, CB, OB, DF, AN, SK and GdH were involved in acquisition of data. KR, DJ, GdH and SK contributed to analysis and interpretation of data. KR drafted the manuscript. KR, CFW, AN, SK and GdH were involved in critical revision of the manuscript for important intellectual content. SK participated in supervision. All authors read and approved the final manuscript.

Acknowledgements

The authors would thank all the participating hospitals for their valuable work and enthusiasm providing clinical data for this study. The authors thank the Hamburg COVID-19 ICU-Study Group Members: Dr. Serap Yilmaz (Asklepios Hospital Harburg), Dr. Robert Schiewe (Asklepios Hospital St. Georg), Dr. Michael Mönk (Asklepios Hospital Wandsbek), Dr. Maja Iversen (Bundeswehr Hospital), Dr. Hans-Richard Paschen (Amaile Sieveking Hospital), Dr. Mirko Horintrich and Dr. Anna Brägelmätt (Albertinen Hospital), Dr. Antje Holst (Agaplesion Diaikon Hospital Hamburg), Peter Baltes and Gesine Janssen (Bethesda Hospital Bergedorf), Dr. Nikolaus Mangold (Asklepios West Hospital Hamburg), Dr. Matthias Wiekern and Dr. Phillip Merkel (Asklepios Hospital North), and Marc Freitag (Israelitische Hospital), and the authors thank the study nurses for their tremendous support: Grit Ringeis, Melanie Kerinn, Lisa Krebs, and Andrea Conrad (University Medical Center Hamburg-Eppendorf) and Marion Redlefsen (Marien Hospital)

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.aacc.2020.10.009.

References

[1] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhnan, China. Lancet 2020;395(10233):497–506.
[2] Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhnan, China: a descriptive study. Lancet 2020;395(10223):507–13.
[3] Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382(18):1708–20.
[4] WHO. WHO—world map—COVID-19 2020 [Available from: https://covid19.who.int/]—Accessed online: [September, 19th 2020].
[5] Grasselli G, Pesenti A, Cecconi M. Critical care utilization for the COVID-19 outbreak in Lombardy, Italy: early experience and forecast during an emergency response. JAMA 2020;323(16):1545–6.
[6] Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA 2020;323(20):2025–9.
[7] Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-COV-2 admitted to ICUs of the Lombardy region, Italy. JAMA 2020;323(16):1624.
[8] Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 2020 Jul 1;180(7):934–43.
[9] Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med 2020;46(5):846–8.
[10] Bhattraj PK, Ghaissemieh B, Nichols M, Kim R, Jerome KR, Nalla AK, et al. Covid-19 in critically ill patients in the seattle region—case series. N Engl J Med 2020;382(21):2012–22.
[11] Arenz T, Yin E, Klafl L, Lokhandwala S, Riedo FX, Chong M, et al. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington state. JAMA 2020;323(16):1612–4.
[12] Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395(10229):1054–62.
[13] Dondorp AM, Hayat M, Ardal Y, Beane A, Schultz MJ. Respiratory support in COVID-19 patients, with a focus on resource–limited settings. Am J Trop Med Hyg 2020;102(5):1191–7.
[14] Arukumaran N, Brealey D, Howell D, Singer M. Use of non-invasive ventilation for patients with COVID-19: a cause for concern? Lancet Respir Med 2020;8(6):e45.
[15] Tobin MJ, Laghi F, Juhan A. Caution about early intubation and mechanical ventilation in COVID-19. Ann Intensive Care 2020;10(1):78.
[16] Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, et al. Acute respiratory distress syndrome: the Berlin Definition. JAMA 2012;307(23):2526–33.
[17] Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third international Consensus definitions for Sepsis and septic shock (Sepsis-3). JAMA 2016;315(8):801–10.
[18] Vincent JL, Moreno R, Takala J, Willatts S, De Mendonça A, Bruhn H, et al. The SOFA (Sepsis-related organ failure assessment) score to describe organ dysfunction/failure. On behalf of the working group on sepsis-related problems of the European society of intensive care medicine. Intensive Care Med 1996;22(7):707–10.
[19] Charbonnier ME, Pompei P, Alex KL, Mackenzie CR. A new method of classifying prognostic confidentiality in longitudinal studies: development and validation. J Chron Dis 1987;40(5):373–83.
[20] Kluge S, Janssens U, Wieland P, Weber-Castrens S, Marx G, Karagiannidou C. German recommendations for critically ill patients with COVID-19. Med Klin Intensivmed Notfmed 2020;1–4.
[21] Alhazzani W, Möller MH, Arabi YM, Loeb M, Gong MN, Fan E, et al. Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19). Intensive Care Med 2020;46(5):854–87.
[22] Grensemann J, Simon M, Kluge S. Airway management in intensive care and emergency medicine: what is new? Med Klin Intensivmed Notfmed 2019;114(4):334–41.
[23] von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007;370(9596):1453–7.
[24] Wang K, Zhao W, Li J, Shu W, Duan J. The experience of high-flow nasal cannula in hospitalized patients with 2019 novel coronavirus-infected pneumonia in two hospitals of Chongqing, China. Ann Intensive Care 2020;10(1):37.
[25] Ferreryo BL, Angirman F, Munshi L, Del Sorbo L, Ferguson ND, Rochwerg B, et al. Association of noninvasive oxygenation strategies with all-cause mortality in adults with acute hypoxemic respiratory failure: a systematic review and meta-analysis. JAMA 2020 Jul 7;324(1):57–67.
[26] Quah P, Li A, Phua J. Mortality rates of patients with COVID-19 in the intensive care unit: a systematic review of the emerging literature. Crit Care (Lond, Engl) 2020;24(1):285.
[27] Villar J, Blanco J, Añón JM, Santos-Bouza A, Blanch L, Ambros A, et al. The ALIEN study: incidence and outcome of acute respiratory distress syndrome in the era of lung protective ventilation. Intensive Care Med 2011;37(12):2013–21.
[28] Karagianidou C, Mostert C, Hentscheler C, Voshaar T, Malzahn J, Schillingger G, et al. Case characteristics, resource use, and outcomes of 10 021 patients with COVID-19 admitted to S20 German hospitals: an observational study. Lancet Respir Med 2020 Sep;8(9):831–62.
Nachtigall I, Lenga P, Jóźwiak K, Thürmann P, Meier-Hellmann A, Kuhlen R, et al. Clinical course and factors associated with outcomes among 1904 patients hospitalized with COVID-19 in Germany: an observational study. Clin Microbiol Infect 2020 Aug 18. S1198-743X(20)30493-6.

Bellani G, Laffey JG, Pham T, Fan E, Brochard L, Esteban A, et al. Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. JAMA 2016;315(8):788–800.

Auld SC, Caridi-Scheible M, Blum JM, Robichaux C, Kraft C, Jacob JT, et al. ICU and ventilator mortality among critically ill adults with coronavirus disease 2019. Crit Care Med 2020 Sep;48(9):e799–804.

Yang X, Cai S, Luo Y, Zhu P, Hu M, Zhao Y, et al. Extracorporeal membrane oxygenation for coronavirus disease 2019-induced acute respiratory distress syndrome: a multicenter descriptive study. Crit Care Med 2020 Sep;48(9):1289–95.

Combes A, Hajage D, Capellier G, Demoule A, Lavoué S, Guervilly C, et al. Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome. N Engl J Med 2018;378(21):1965–75.

Shao F, Xu S, Ma X, Xu Z, Lyu J, Ng M, et al. In-hospital cardiac arrest outcomes among patients with COVID-19 pneumonia in Wuhan, China. Resuscitation 2020;151:18–23.

Wichmann D, Sperhake JP, Lütgehetmann M, Steurer S, Edler C, Heinemann A, et al. Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study. Ann Intern Med 2020 Aug 18;173(4):268–77.

Langer F, Kluge S, Klamroth R, Oldenburg J. Coagulopathy in COVID-19 and its implication for safe and efficacious thromboprophylaxis. Hämostaseologie 2020;40(3):264–9.